Crossmark

Angiotensin-(1–7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1–2 randomized clinical trial

Crossref DOI link: https://doi.org/10.1186/s13613-024-01369-0

Published Print: 2024

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Martins, Ana Luiza Valle

Annoni, Filippo

da Silva, Filipe Alex

Bolais-Ramos, Lucas

de Oliveira, Gisele Capanema

Ribeiro, Renata Cunha

Diniz, Mirella Monique Lana

Silva, Thuanny Granato Fonseca

Pinheiro, Beatriz Dias

Rodrigues, Natália Abdo

dos Santos Matos, Alana Helen

Motta-Santos, Daisy

Campagnole-Santos, Maria José

Verano-Braga, Thiago

Taccone, Fabio Silvio

Santos, Robson Augusto Souza
Clinical Trials ^BETA

Clinical trials referenced in this document:

nct04633772 at ClinicalTrials.gov

Documents that mention this clinical trial

Angiotensin-(1–7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1–2 randomized clinical trial
https://doi.org/10.1186/s13613-024-01369-0
Funding

Funding for this research was provided by:

Université Libre de Bruxelles (5C06G000010)

FAPEMIG (APQ-00325-20)
License Information

Text and Data Mining valid from 2024-01-01

Text and Data Mining valid from 2024-01-01

Version of Record valid from 2025-11-19
More Information

This article is maintained by: Elsevier

Article Title: Angiotensin-(1–7) infusion in COVID-19 patients admitted to the ICU: a seamless phase 1–2 randomized clinical trial

Journal Title: Annals of Intensive Care

CrossRef DOI link to publisher maintained version: https://doi.org/10.1186/s13613-024-01369-0

Content Type: article

Copyright: Copyright © 2024 The Author(s) 2024. Published by Elsevier Masson SAS